Get 25% off an annual STAT+ subscription and read more of our award-winning journalism. www.statnews.com Join the STAT+ community today to get access to last month's top stories and much more. Subscribe now for 25% off your first year. HYACINTH EMPINADO/STAT Here are the worst biopharma CEOs of 2023 by Adam Feuerstein READ MORE ADOBE Prime Medicine, Mukherjee's Myeloid Therapeutics clash over genome-editing deal by Jason Mast and Allison DeAngelis READ MORE MOLLY FERGUSON/STAT After sickle-cell screwups, Bluebird Bio's only option might be a company sale by Adam Feuerstein READ MORE MORE TOP STORIES UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients by Bob Herman and Casey Ross In the U.S., scientists see barriers to the development of CAR-T cell therapies. In Spain, a hospital brews its own by Andrew JosephIn historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease by Adam FeuersteinMedical marijuana companies are using pharma's sales tactics with little of the same scrutiny by Nicholas FlorkoAmy Abernethy to step down as Verily's chief medical officer in latest departure from company by Matthew HerperWith big ambition — and a family name to match — Reed Jobs charts his own course in biotech by Allison DeAngelisHere are the best biopharma CEOs of 2023 by Adam Feuerstein SUBSCRIBE Thursday, January 4, 2024 1 Exchange Place, Boston, MA 02109 ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us
No comments